Under construction – not a live service
Sign in
Not yet taking people in South KoreaNo phase

Long-term follow-up of FURESTEM-AD in atopic dermatitis

Follows adults with moderate to severe atopic dermatitis after earlier FURESTEM-AD treatment doses.

Plain-language title generated from the registry record
Registry title: Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj

Key facts

Where
Ilsan, South KoreaSee the site

Where in South Korea

  • dongguk University Medical CenterIlsan, South KoreaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Kang Stem Biotech Co., Ltd.
Trial code
NCT04730024
Record updated
29 January 2021
Original description
A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results from the K0104 Extension StudyRead full original descriptionShow less

Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results From the K0104 Extension Study

A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results from the K0104 Extension Study

Inclusion: Subject who enrolled K0104 Clinical Trial(parent study); Subjects who understand and voluntarily sign an informed consent form.

Exclusion: Subjects who has received/administered clinical trial drugs or medical devices by participating in other clinical trials until the first visit of this trial (K0104-E) after the completion of K0104 clinical trial; Subjects who are expected to be unable to perform at least one follow-up during this study (K0104-E); Subjects who are judged to be unsuitable for other researchers to participate in the research.

ClinicalTrials.gov NCT04730024